💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ibuprofen Lysine

CHEMBL1201141 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
352.5 g/mol
LogP
—
Phase
4

This is the lysine salt form of ibuprofen, which may dissolve more quickly than standard ibuprofen, potentially providing faster onset of pain relief. The lysine conjugate improves the solubility of ibuprofen for certain formulations, including intravenous use for closing patent ductus arteriosus in premature infants. It shares the anti-inflammatory, analgesic, and antipyretic properties of ibuprofen.

分子量

352.5000 g/mol

TPSA

127.00 Ų

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Obstetrics & Gynecology Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Urology Stroke Hyperlipidemia Obesity Lymphoma Gastroenterology Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Malaria Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

作用機序

Non-selective COX inhibitor reducing prostaglandin synthesis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Non-selective COX inhibitor reducing prostaglandin synthesis.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C13H18O2.C6H14N2O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15;7-4-2-1-3-5(8)6(9)10/h4-7,9-10H,8H2,1-3H3,(H,14,15);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H32N2O4

                    

                    
                    

                        
HBD / HBA

                        
4 / 6

                    

                    
                    

                        
回転可能結合数

                        
9

                    

                    
                    
                    

                        
重原子数

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This is the lysine salt form of ibuprofen, which may dissolve more quickly than standard ibuprofen, potentially providing faster onset of pain relief. The lysine conjugate improves the solubility of ibuprofen for certain formulations, including intravenous use for closing patent ductus arteriosus in premature infants. It shares the anti-inflammatory, analgesic, and antipyretic properties of ibuprofen.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Non-selective COX inhibitor reducing prostaglandin synthesis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ibuprofen Lysine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201141.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9841440.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.